Danieled Ambrosio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Galapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

United statesItaly generalSan diegoMichele mantoDaniele dambrosioDane leonePaul stoffelsThad hustonVan gijselBrian abrahamsJeevan shettyRaymond jamesClinical development oncologyMost valuable esports companiesHead of clinical development in oncologyCall transcript november

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Region flamandeSandra cauwenberghsVan gijselDaniele dambrosioMarieke vermeerschBritish isles lupus assessment groupExchange commissionComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunologyAktien sie

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases.

Region flamandeDaniele dambrosioMarieke vermeerschSandra cauwenberghsVan gijselBritish isles lupus assessment groupExchange commissionComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunology

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Region flamandeMarieke vermeerschDaniele dambrosioSandra cauwenberghsVan gijselBritish isles lupus assessment groupExchange commissionComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunology

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

Region flamandeSandra cauwenberghsDaniele dambrosioMarieke vermeerschVan gijselExchange commissionBritish isles lupus assessment groupComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunology